review pipelin start scale pt
due sector multipl compress
alexion report sales/earn provid investor updat
compani upgrad financi guidanc includ
top- bottom-lin growth forecast potenti
ep provid extens pipelin launch updat
variou project develop exhibit beat sales/non-gaap
earn comfort surpris step-up expens call
indic spend go revenu go forward
updat model accordingli soliris/ultomiri uptak variou approv
indic continu beat manag expect metabol franchis
growth continu measur fashion stay bullish
postul last quarter midst
sales/earn beat rais cycl replenish pipelin manag
exceed expect manag engag thought
deal achn purchas etc strong soliri mg newli approv nmosd
launch on-going ultomiri convers pnh continu apac
opex trend burgeon pipelin soliris/ultomiri
convers hit mainten phase ultomiri average cheaper yr
expect volatil earn progress potenti margin compress
current high main reason below-consensu earn
estim look guidanc opex trend greater visibl
ultomiri pnh convers continu strongli forecast ww
convers combin franchis demonstr revenu
growth beat expect soundli channel check
survey work point pnh convers rate closer
time-frame recent approv ahu indic commentari
indic measur uptak
pipelin steer away relianc pnh/ahu
becom highli competit especi intrigu ultomiri al
phase studi initi preclin mous data suggest activ
around complement signal axi expect subq ultomiri
data dose option increas option patient
range-bound sinc compani
experienc near multipl compress believ concern around
competit core pnh/ahu franchis kept share re-rat
biotech sector lost luster reduc
pt reflect sector woe rais est stay bullish
year price histori
alexion global biopharmaceut
compani focus develop
deliv life-transform therapi
patient devast
analyst certif import disclosur see disclosur
launch kanuma strensiq keep gain traction
kanuma upsid wild card leverag
oper platform identifi patient drive sale time
soliri continu expand gmg
ultomiri pnh hit convers year
fx macro tailwind positive/neutr sale adjust ep
addit data ahu posit
rate alexion outperform pt
believ compani risk/reward profil orient
upsid new execution-focus manag strong
fundament increas transpar reduct fx/
gener asset soliri continu expand label two
newli launch product strensiq kanuma believ
question rather share posit re-rat
initi ultomiri phase nmosd
enrol complet phase studi wilson diseas
addit catalyst see exhibit
kanuma strensiq launch ramp quickli expect
due histori robust patient identif
soliri label expans upsid greater expect
ultomiri pnh convers year achiev
gain oper leverag kanuma strensiq launch
near term
fx macroeconom headwind put downward pressur outer
year sale adjust ep estim
soliri label expans yield posit result
ultomiri pnh convers year
brand competit biosimilar soliri reduc number
commerci patient near term take signific market
share medium/long term
data/uptak wors expect
rate outperform price target due sector price-to-earnings multipl compress util composit valuat
methodolog biotechnolog compani base forward price-to-earnings multipl net present valu adjust non-gaap estim
earn sinc biotechnolog high-growth/high-expect sector aim rank target compani base qualiti sale
and/or earn growth versu peer group
risk faster slow soliri sale label-extens pipelin failur and/or regulatori non-approv falter strensiq
kanuma sale ramp clinic trial failur key mid-/long-term product manag turnov creat strateg uncertainti
sale investig lead materi impact soliri sale go forward
opcovariancenet product revenue- total chang conting liabil ip settlements- total cost research sell gener acquisition-rel costs- impair intang assets- amort purchas intang assets- chang conting liability- restructur expenses- non-gaap oper non-gaap oper non-gaap invest interest foreign currenc non-gaap incom incom incom tax non-gaap net dilut dilut share alexion pharmaceut
exhibit progress
exhibit ultomiri us convers progress guidanc
exhibit soliri ultomiri net product sale
launch pnh convers ultomiri launch pk studi data sc commerci phase studi wilson diseas anticip earli enrol launch jp approv eu launch phase studi phase studi registr phase trial poc studi ppmshematolog phase pk-base phase studi deliv subcutan per week support registr pnh ahu data expect earli phase al phase data phase studi phase studi data rare immunoglobulin igg -mediat autoimmun patient convers ultomiri achillion pend transact top-line result pnh patient clinic extravascular studi complet studi pnh initi upon regulatori feedbackstealth pend option data pmm primari mitochondri meet disucss nda submiss barth syndromeearli phase lhon leber hereditari optic phase enrol ga attr initi japan pend regulatori discuss outperform
valuat cagrcommentsproduct revenu growth ebitda net incom y/i growth growth us adj ep compound-annual-growth-rate group index nbi indexp group adj ep compound-annual-growth-rate group termin price-to-earnings multipl multipl large-cap peer group oppenheim estim us termin price-to-earnings multipl peer group due qualiti sale ep growthtermin valu us wacc peer group larg cap biotech averag per bloomberg us discount rate adj ep price-to-earnings valuat alexion pharmaceut
alexion pharmaceut statement million except per product revenue- total chang conting liabil ip settlements- total cost research sell gener acquisition-rel costs- impair intang assets- amort purchas intang assets- chang conting liability- restructur expenses- non-gaap oper non-gaap oper non-gaap invest interest foreign currenc non-gaap incom incom incom tax non-gaap net dilut dilut share comp oper outperform
stock price compani mention report
